Com a sua autorização, usamos análises limitadas e respeitadoras da privacidade para perceber que percursos de investigação funcionam. Não usamos rastreadores publicitários nem gravação de sessões. Pode alterar esta escolha nas Preferências. Leia a Política de Privacidade.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
REGN — frequently asked questions
Is Regeneron Pharmaceuticals Inc. overvalued?
In our latest published analysis dated 2026-05-10, REGN looks meaningfully undervalued. The price recorded at analysis is USD 715 versus our fair value of USD 1.210; the high endpoint is presented separately as potential value of USD 1.505. That implies roughly 69.2% upside to fair value at that date.
Our latest published report, analyzed 2026-05-10, gives REGN a fair value of USD 1.210 and a potential value of USD 1.505. The conclusion is triangulated across multiple valuation models and weighted by reliability for Regeneron Pharmaceuticals Inc.'s archetype; it is a dated research output, not a live price.
Should I buy REGN now?
Our latest published rating for REGN, analyzed 2026-05-10, is Strong Buy. Regeneron Pharmaceuticals Inc. looks meaningfully undervalued at the analysis-date price of USD 715 versus fair value of USD 1.210; potential value is USD 1.505. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for REGN?
The dedicated bear-case section in our report analyzed 2026-05-10 documents Regeneron Pharmaceuticals Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is REGN's rating?
Our latest published rating for REGN, analyzed 2026-05-10, is Strong Buy, with a published moat assessment of 9/10 (Wide). It reflects our fair value of USD 1.210, the potential value of USD 1.505, and the price recorded at analysis (USD 715).
Este relatório ainda não foi traduzido. Atualize em alguns minutos assim que a fila de tradução recuperar o atraso.
§1 Resumo executivoEN
Resposta em 30 segundosStrong Buy
Preço versus valor
Preço
$714.89
Valor justo
$1,209.72
Valor potencial
$1,505.07
Em
Data da cotação não registrada
Por que pode funcionar
Bull: Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion.
O que mudaria nossa visão
High-Dose Eylea Fails to Defend Share: Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Patented core commercial assets in
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Cycle upside
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Recomendação da casa
Strong Buy. The downside is fundamentally fully priced in, while the long-term compounder cash profile remains robust and highly intact.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
§2 Cenário pessimistaEN
In a severe downside scenario, Regeneron faces simultaneous shocks: Eylea loses material share to Vabysmo and biosimilars, Dupixent growth sharply decelerates, and pipeline failures force a structural reset in operating margins below 25%. Even under these dire conditions, baseline FCFF generation anchors intrinsic value near $917, indicating the downside is already heavily priced in.
Dupixent hits an earlier-than-expected growth wall.
Operating margins structurally trapped below 25% due to pipeline failures.
In a downside event where core assets erode rapidly and R&D fails to deliver, the stock still holds a baseline value of $917, highlighting the massive margin of safety currently priced into the $714 level.
Como esta tese pode falhar
High-Dose Eylea Fails to Defend Share
Low
Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
FV impact
-25%
Dupixent Growth Wall
Medium
Dupixent matures faster than expected and label expansions underperform, halting the company's primary top-line engine.
FV impact
-15%
Sinais de alerta antecipado para monitorar
Os cinco desenvolvimentos que enfraqueceriam a nossa tese de investimento.
01
Eylea High-Dose Conversion Adoption
Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
Atual:Baseline adoption as of 2026-05-10
Alerta seStalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window
02
§3 Vantagem competitivaEN
Wide
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Scale advantages in manufacturing and clinical trial execution versus smaller biopharma peers.
Lucro econômico
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
9/ 10
Wide
Sources of advantage
01Patented core commercial assets in Dupixent and Eylea generating sticky, recurri — Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.Wide
02VelociSuite R&D engine allowing highly efficient discovery and commercialization — VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.Wide
03Scale advantages in manufacturing and clinical trial execution versus smaller bi — Scale advantages in manufacturing and clinical trial execution versus smaller biopharma peers.Wide
Ameaças conhecidas à vantagem competitiva
Ameaça
Gravidade
Cronograma
Mitigação
Approaching patent cliffs and high-dose Eylea biosimilar threats.
medium
Monitor
Monitor the threat against the report checkpoints.
Competition from Roche/Genentech and targeted therapies like Vabysmo.
Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Em linha
Hold
Gatilho: In-line results
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Aquém
Reassess
Gatilho: Downside surprise
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Qualidade dos lucros
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Métricas a observar antes do anúncio
01
Métrica:
Eylea High-Dose Conversion Adoption
AtualBaseline adoption as of 2026-05-10
Por que importa
Warning level: Stalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window. Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
Receita mais recente14,3 biCAGR da receita +5,6%
Margem operacional25,8%5 períodos fiscais
Fluxo de caixa livre mais recente3,8 biFY2025
Caixa líquido412,2 miFY2025
Detalhamento da demonstração de resultadosComo a escala do negócio se converte em lucro reportado.
StockMarketAgent.AI
Receita14,3 biCusto das receitas−2,1 biLucro bruto12,2 biDespesas operacionais−8,5 biLucro operacional3,7 biItens não operacionais e impostos+802,9 miLucro líquido4,5 bi
Dados do histórico financeiro
Receita
14.342.900.000
Custo das receitas
2.100.700.000
Lucro bruto
12.242.200.000
Despesas operacionais
8.540.200.000
Lucro operacional
3.702.000.000
Itens não operacionais e impostos
802.900.000
Lucro líquido
4.504.900.000
Visão geral do balançoComo os ativos reportados são mantidos e financiados no período selecionado.
REGN trades at 13.3x forward earnings against a peer median of 19.9x; EV/EBITDA of 15.2x against a peer median of 20.8x; 6 peers.
§10 Setor e cicloEN
Fase do ciclo
Expansion
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
Ciclo de alta
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Ciclo de baixa
Regulatory pricing pressures compound with aggressive biosimilar substitution, severely discounting terminal multiples across mature biopharma.
Posicionamento
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
§11 Gestão de posiçãoEN
Dimensionamento
Core holding for large-cap growth allocations. Sizing should confidently reflect the robust margin of safety.
Risco
Trim exposure if shares approach the $1,200 fair value mid-point, or if high-dose Eylea fails to retain 50%+ share over a 12-month trailing period.
Tranches de entrada
Nível
Ação
Por quê
Current / pullbacks
Accumulate aggressively at current levels ($714), as the market is overly penalizing transient R&D investments.
Accumulate aggressively at current levels ($714), as the market is overly penalizing transient R&D investments.
Tranches de saída
Nível
Ação
Thesis break
Trim exposure if shares approach the $1,200 fair value mid-point, or if high-dose Eylea fails to retain 50%+ share over a 12-month trailing period.
§12 Perspectivas dos investidoresEN
Bull view
Buy
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
Base view
Buy
The 38.2% gap versus the $875.31 internal valuation cross-checks underscores a myopic market fixation on transient R&D spending and peak patent cliff fears, completely ignoring the underlying cash-generation power of VelociSuite.
§14 Recomendação finalEN
Ação
Compra forte
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
Atual:25.8% for the period ended 2025-12-31
Alerta seCompresses below 25.0% over any trailing twelve-month period
04
Late-Stage Clinical Asset Development
Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Atual:$5.8B annual R&D spend as of 2026-05-10
Alerta seFiled clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window
A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
Atual:12.3% as of 2026-05-10
Alerta seBreaks below 10.0% as of any annual measurement date
Monitor
Monitor the threat against the report checkpoints.
Concentration risk given outsized revenue contribution from Dupixent.
medium
Monitor
Monitor the threat against the report checkpoints.
Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.
Warning level: Compresses below 25.0% over any trailing twelve-month period. A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
04
Métrica:
Late-Stage Clinical Asset Development
Atual$5.8B annual R&D spend as of 2026-05-10
Por que importa
Warning level: Filed clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window. Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Warning level: Breaks below 10.0% as of any annual measurement date. A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
